130 related articles for article (PubMed ID: 22223544)
1. An event-based approach for comparing the performance of methods for prospective medical product monitoring.
Gagne JJ; Walker AM; Glynn RJ; Rassen JA; Schneeweiss S
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):631-9. PubMed ID: 22223544
[TBL] [Abstract][Full Text] [Related]
2. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules.
Gagne JJ; Rassen JA; Walker AM; Glynn RJ; Schneeweiss S
Epidemiology; 2012 Mar; 23(2):238-46. PubMed ID: 22266893
[TBL] [Abstract][Full Text] [Related]
3. Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study.
Van Holle L; Zeinoun Z; Bauchau V; Verstraeten T
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):603-10. PubMed ID: 22383219
[TBL] [Abstract][Full Text] [Related]
4. Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.
Bailey S; Singh A; Azadian R; Huber P; Blum M
Drug Saf; 2010 Feb; 33(2):139-46. PubMed ID: 20082540
[TBL] [Abstract][Full Text] [Related]
5. A Comparison Study of Algorithms to Detect Drug-Adverse Event Associations: Frequentist, Bayesian, and Machine-Learning Approaches.
Pham M; Cheng F; Ramachandran K
Drug Saf; 2019 Jun; 42(6):743-750. PubMed ID: 30762164
[TBL] [Abstract][Full Text] [Related]
6. Comparison of text processing methods in social media-based signal detection.
Gavrielov-Yusim N; Kürzinger ML; Nishikawa C; Pan C; Pouget J; Epstein LB; Golant Y; Tcherny-Lessenot S; Lin S; Hamelin B; Juhaeri J
Pharmacoepidemiol Drug Saf; 2019 Oct; 28(10):1309-1317. PubMed ID: 31392844
[TBL] [Abstract][Full Text] [Related]
7. The impact of exposure model misspecification on signal detection in prospective pharmacovigilance.
van Gaalen RD; Abrahamowicz M; Buckeridge DL
Pharmacoepidemiol Drug Saf; 2015 May; 24(5):456-67. PubMed ID: 25187155
[TBL] [Abstract][Full Text] [Related]
8. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
[TBL] [Abstract][Full Text] [Related]
9. Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance.
van Gaalen RD; Abrahamowicz M; Buckeridge DL
Drug Saf; 2017 Nov; 40(11):1119-1129. PubMed ID: 28664355
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
[TBL] [Abstract][Full Text] [Related]
11. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
Zhou Z; Hultgren KE
JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
[TBL] [Abstract][Full Text] [Related]
12. Comparison of three methods (consensual expert judgement, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions: an assessment using reports made to a French pharmacovigilance centre.
Théophile H; Arimone Y; Miremont-Salamé G; Moore N; Fourrier-Réglat A; Haramburu F; Bégaud B
Drug Saf; 2010 Nov; 33(11):1045-54. PubMed ID: 20925441
[TBL] [Abstract][Full Text] [Related]
13. Pediatric drug safety signal detection: a new drug-event reference set for performance testing of data-mining methods and systems.
Osokogu OU; Fregonese F; Ferrajolo C; Verhamme K; de Bie S; 't Jong G; Catapano M; Weibel D; Kaguelidou F; Bramer WM; Hsia Y; Wong IC; Gazarian M; Bonhoeffer J; Sturkenboom M
Drug Saf; 2015 Feb; 38(2):207-17. PubMed ID: 25663078
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance.
Roux E; Thiessard F; Fourrier A; Bégaud B; Tubert-Bitter P
IEEE Trans Inf Technol Biomed; 2005 Dec; 9(4):518-27. PubMed ID: 16379369
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.
Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y
Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447
[TBL] [Abstract][Full Text] [Related]
16. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker.
Berlin C; Blanch C; Lewis DJ; Maladorno DD; Michel C; Petrin M; Sarp S; Close P
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):622-30. PubMed ID: 21994119
[TBL] [Abstract][Full Text] [Related]
17. Structured assessment for prospective identification of safety signals in electronic medical records: evaluation in the health improvement network.
Cederholm S; Hill G; Asiimwe A; Bate A; Bhayat F; Persson Brobert G; Bergvall T; Ansell D; Star K; Norén GN
Drug Saf; 2015 Jan; 38(1):87-100. PubMed ID: 25539877
[TBL] [Abstract][Full Text] [Related]
18. Data mining in pharmacovigilance--detecting the unexpected: the role of index of suspicion of the reporter.
Sundström A; Hallberg P
Drug Saf; 2009; 32(5):419-27. PubMed ID: 19419236
[TBL] [Abstract][Full Text] [Related]
19. A computerized adverse drug event alerting system using clinical rules: a retrospective and prospective comparison with conventional medication surveillance in the Netherlands.
Rommers MK; Teepe-Twiss IM; Guchelaar HJ
Drug Saf; 2011 Mar; 34(3):233-42. PubMed ID: 21332247
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of statistical approaches to postmarketing surveillance.
Ding Y; Markatou M; Ball R
Stat Med; 2020 Mar; 39(7):845-874. PubMed ID: 31912927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
